DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for spindle cell hemangioma — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSpindle cell hemangioma maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for spindle cell hemangioma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
isocitrate dehydrogenase (NADP(+)) 2 (IDH2) — IDH2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ndpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5I96 · 1.55 Å · ligand NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NDP). Experimental structure, not a prediction.
What the evidence adds up to
Spindle cell hemangioma is a rare vascular tumour, with only a few hundred cases described in the literature. The largest case series analysed here includes eight patients. The tumour typically presents as a small subcutaneous nodule under 2 cm on the extremities of young people, but case reports document it in the cervix (a 10-cm mass extending to the retroperitoneum in a 39-year-old woman), the orbit (a large tumour in a 9-year-old girl), and the lung. Recurrence after resection is noted as a tendency, but no systemic therapy or drug treatment is mentioned in any of these reports.
The 2022 molecular analysis of eight cases found that IDH1/2 gene hotspot mutations are specific to spindle cell hemangioma among vascular lesions. The authors state that genetic detection can help in diagnosing challenging cases, but they do not report any drug target, treatment response, or survival data. No abstract provides information on response rates, progression-free survival, or overall survival for any drug.
No drug is named in any of these abstracts. The standard management described is surgical resection, and no medical therapy is discussed. There is no evidence from these reports for any pharmacological intervention, repurposed or otherwise.
What is missing is any clinical trial testing a drug for this condition, any patient stratification beyond histology and IDH mutation status, and any funding for such a trial. Without those, the natural history of spindle cell hemangioma remains defined only by surgical case series.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Gynecologic and Obstetric Investigation · 2005 · 13 citations
Huge Spindle Cell Hemangioma of the Cervix – Mimicking a Pelvic Tumor
AbstractBACKGROUND: Spindle cell hemangiomas are rare vascular tumors characterized by cavernous blood vessels and spindled areas reminiscent of Kaposi's sarcoma. Cervical hemangiomas are rare, and the spindle cell subtype is rarer still. CASE: Examination of a 39-year-old patient presenting with pelvic pain revealed a remarkable pelvic mass consisting of a 10-cm tumor extending from the cervix to the retroperitoneum. The pathology report demonstrated spindle cell hemangioma. CONCLUSION: This is a rare case of spindle cell hemangioma of the cervix resected transvaginally.
Journal of Oral and Maxillofacial Pathology · 2015 · 12 citations · open access
Spindle cell hemangioma: Unusual presentation of an uncommon tumor
AbstractSpindle cell hemangioma (SCH) is an uncommon tumor that usually presents as subcutaneous or deep dermal nodule affecting the extremities and is typically <2 cm in size. A few cases have been reported in the head and neck region. To the best of the authors' knowledge, there are no previous reports of SCH occurring in the orbit in the English literature. We, therefore, report the case of a large SCH involving the right orbit of a healthy 9-year-old Nigerian girl.
Spindle Cell Hemangioma of the Lung: A Case Report
AbstractSpindle cell hemangioma (SCH) is an uncommon tumor that usually presents as a subcutaneous or deep dermal nodule affecting the extremities of young people. It is primarily a benign vascular neoplasm with a tendency to recur locally. Reports describing SCH diagnosed in muscles, retroperitoneum, mediastinum, and even in the spinal cord occasionally surface in the literature. We report a very rare case of SCH diagnosed in the lung.
[Spindle cell hemangioma: a clinicopathological and molecular analysis of eight cases].
AbstractSCH is rare and should be differentiated from a variety of benign and malignant vascular lesions. An accurate diagnosis of SCH is clinically important and can be achieved by combining clinical information and typical pathological presentation. IDH1/2 gene hotspot mutations are specific to SCH in vascular lesions. Genetic detection is helpful in the diagnosis of challenging cases.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
